Related Experiment Video

Updated: Sep 22, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

One drug for childhood grand mal: medical audit for three-year remissions

W I Forsythe, M A Sills

    Developmental Medicine and Child Neurology
    |December 1, 1984
    PubMed

    Insights

    Carbamazepine and phenytoin show better seizure remission rates in children with grand mal epilepsy compared to phenobarbitone and sodium valproate. Further research is needed for effective treatments in non-responders.

    Area of Science:

    • Pediatric Neurology
    • Clinical Pharmacology

    Background:

    • Grand mal seizures are a common form of epilepsy in children.
    • Monotherapy is a standard treatment approach for managing pediatric epilepsy.

    Purpose of the Study:

    • To compare the efficacy of four first-choice anticonvulsants in children with grand mal seizures.
    • To evaluate treatment outcomes based on seizure type (primary vs. secondary grand mal).

    Main Methods:

    • A comparative study involving 585 children aged 3-14 years.
    • Four groups received monotherapy with phenobarbitone, phenytoin, carbamazepine, or sodium valproate.
    • Seizure remission rates were assessed over a three-year period.

    Main Results:

    • Carbamazepine (40%) and phenytoin (34%) demonstrated higher three-year seizure remission rates than phenobarbitone (22%) and sodium valproate (16%).
    • Outcomes were more favorable for primary grand mal seizures across all drug groups.
    • Children with secondary grand mal showed significantly lower remission rates, particularly with phenobarbitone (3%) and sodium valproate (4%).

    Conclusions:

    • Carbamazepine and phenytoin appear to be more effective first-line treatments for pediatric grand mal seizures.
    • The study highlights a critical need for novel anticonvulsant therapies for children with secondary grand mal epilepsy and those unresponsive to current treatments.

    More Related Videos

    Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy10:22

    Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

    Published on: December 6, 2016

    Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy09:57

    Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

    Published on: September 20, 2024

    Related Concept Videos

    Drug Regulation01:25

    Drug Regulation

    Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

    Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
    SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...